Pembrolizumab was well tolerated, brought a rapid clinical improvement after the first dose with a decrease in abdominal swelling and pain, and reduced levels of the tumor markers carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9, see Figure 4). This evidence concerns the gene CEACAM5 and neoplasm.